Alpha-2A-adrenergic receptor polymorphisms
The present invention includes polymorphisms in nucleic acids encoding the alpha-2A adrenergic receptor and expressed alpha-2A adrenergic receptor molecule. The invention also pertains to methods and molecules for detecting such polymorphisms and transgenic animals expressing alpha-2A adrenergic receptor molecules. The invention further pertains to the use of such molecules and methods in the diagnosis, prognosis, and treatment of diseases such as cardiovascular and central nervous system diseases.
1. A method for identifying a human at increased risk for developing a physiological function associated with an alpha-2A adrenergic receptor molecule comprising a lysine at amino acid 251, said method comprising the steps of obtaining information associated with a sample from the human, said information indicating the presence or absence of lysine at amino acid 251 of an alpha-2A adrenergic receptor molecule; and identifying the human at increased risk for the physiological function if lysine is present at amino acid 251 of alpha-2A adrenergic receptor molecule, wherein the physiological function is selected from an enhanced inhibition of adenylyl cyclase and enhanced stimulation of MAP kinase by the alpha-2A adrenergic receptor in response to an agonist, wherein the agonist is selected from the group consisting of a catecholamine, an azepine, and an imadazoline.
2. The method of claim 1 , wherein said information is obtained using a nucleic acid based assay.
3. The method of claim 1 , wherein the agonist is a catecholamine.
4. The method of claim 1 , wherein the agonist is an azepine.
5. The method of claim 1 , wherein the agonist is an imadazoline.